Navigation Links
European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
Date:5/14/2012

LONDON, May 14, 2012 /PRNewswire/ -- The increasing incidence of thrombosis, paralleled by the maturing life cycles of existing products, are motivating the need for novel alternatives. Establishing end-user confidence and ensuring cost-effectiveness pose significant challenges to market advancement. However, the launch of three blockbuster oral anticoagulants is projected to help the thrombosis therapeutics market address these challenges. It is also anticipated to help companies tackle competition from low cost generics. 

New analysis from Frost & Sullivan (http://www.pharma.frost.com), Analysis of the European Thrombosis Therapeutics Market, finds that the market earned revenues of approximately $8.67 billion in 2010 and estimates this to reach approximately $13.01 billion in 2017 at a compound annual growth rate (CAGR) of 6.6 per cent from 2010-2017.

"The rising number of people suffering from thrombosis is resulting in higher demand for related therapeutics," notes Frost & Sullivan Research Analyst Deepika Pramod Chopda. "This, coupled with strong pipeline development, is pushing robust growth in the overall market."

About 4.5 million people in Europe are diagnosed with thrombosis annually, underlining the growing incidence of the disease. The result has been higher demand for treatment, complementing overall market growth. Approximately $3.46 billion was spent on R&D, indicative of vigorous efforts to develop innovative thrombotic drugs.

A key challenge has been the competition from generic manufacturers that are able to offer cost-effective equivalents to patented brands.

"The loss of patent rights of established thrombosis drugs in the early stages of the forecast period will contribute to the rise of generics," explains Deepika. "These low cost substitutes are likely to hinder the adoption of new and improved products."

Stringent approval procedures are also hampering market expansion. The European Medicines Agency (EMA) assesses several factors at every level of a drug's progress. This rigorous process limits the number of new medicines entering the market.

"Awareness raising through public healthcare forums and organisations about new developments and innovative treatment options will contribute towards establishing greater end-user confidence," concludes Deepika. "In the meantime, precautionary measures like adopting healthy lifestyle practices will help limit the incidence of the disease."

If you are interested in more information on this study, please send an e-mail with your contact details to Janique Morvan, Corporate Communications, at janique.morvan@frost.com.

Analysis of the European Thrombosis Therapeutics Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Biosimilars Market, Generic Pharmaceuticals Market – A Global Analysis and European Pharmaceutical and Biotech Contract Manufacturing Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Analysis of the European Thrombosis Therapeutics Market
M74C-52

Contact:
Janique Morvan
Corporate Communications – Europe
P: +33 (0)1 42 81 20 37
M: +33 (0)6 79 22 41 42
E: janique.morvan@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Lipitor® in Five European Countries
2. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
3. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
4. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
5. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
6. Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries
7. Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries
8. Dune Medical Devices Hosts Symposium Featuring MarginProbe® System at European Breast Cancer Conference
9. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
10. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
11. BioStorage Technologies Integrates Sample Preparation Services into European Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2020)... ... ... Each year Therapy and Beyond, a leading ABA provider across Texas, ... for 100+ moms of children with autism. This event allows moms to mingle with ... carefree fun. The highly anticipated 3rd annual North Houston Mom’s Mingle will be held ...
(Date:1/23/2020)... ... January 23, 2020 , ... In the largest ... 102 genes associated with risk for autism. The study also shows significant progress ... disability and developmental delay, conditions which often overlap. The study results are published ...
(Date:1/23/2020)... Calif. (PRWEB) , ... January 23, 2020 , ... ... a Meridian Senior Living assisted living community, has received a deficiency-free ... , “We’re very excited to receive a deficiency-free survey from the State,” said ...
Breaking Medicine Technology:
(Date:1/24/2020)... Ariz. (PRWEB) , ... January 24, 2020 , ... ... is teaming up with celebrity fitness expert and best-selling nutrition author Jorge Cruise ... sugars and intermittent fasting. , “I’m an enthusiastic advocate of intermittent fasting, that ...
(Date:1/23/2020)... ... January 23, 2020 , ... The Icahn School of ... and patient care—today announced the recipients of the first-of-its-kind Distinguished Scholar Award, a ... Medicine. The awards aim to mitigate gender gaps in medical research by supporting ...
(Date:1/23/2020)... , ... January 23, 2020 , ... A January 7 ... options to get rid of them. The article quotes the president of the American ... double-chin are many. They can be caused by a person’s facial structure including an ...
(Date:1/23/2020)... ... January 23, 2020 , ... Worldwide Business with ... Brand Director, Michelle Berger and Vice President of Dairy and Frozen, Jimmy Farber ... is a company that creates organic food and snack options at an affordable price. ...
(Date:1/23/2020)... ... 2020 , ... DelawareBio, a nonprofit trade organization with the ... on gene editing that goes beyond CRISPR technology. To be held Thursday, February ... event will provide an overview of the opportunities and challenges expected in bringing ...
Breaking Medicine News(10 mins):